Quick answers
- What is Sulfacetamide sodium and prednisolone sodium phosphate used for?
- The FDA-approved label (Sulfacetamide Sodium and Prednisolone Sodium Phosphate, NuCare Pharmaceuticals,Inc., July 15, 2024) says: “Sulfacetamide Sodium and Prednisolone Sodium Phosphate Ophthalmic Solution is indicated for corticosteroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the side effects of Sulfacetamide sodium and prednisolone sodium phosphate?
- The “Adverse Reactions” section of the FDA label (Sulfacetamide Sodium and Prednisolone Sodium Phosphate, NuCare Pharmaceuticals,Inc., July 15, 2024) begins: “Adverse reactions have occurred with corticosteroid/anti-infective combination drugs which can be attributed to the corticosteroid component, the anti-infective component, or the combination. Exact incidence figures are not available since no denominator of treated patients is available. Reactions occurring most often from the presence of the anti-infective ingredient are allergic sensitizations.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the drug interactions of Sulfacetamide sodium and prednisolone sodium phosphate?
- The “Drug Interactions” section of the FDA label (Sulfacetamide Sodium and Prednisolone Sodium Phosphate, NuCare Pharmaceuticals,Inc., July 15, 2024) begins: “Sulfacetamide Sodium and Prednisolone Sodium Phosphate Ophthalmic Solution is incompatible with silver preparations. Local anesthetics related to p-aminobenzoic acid may antagonize the action of the sulfonamides.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Sulfacetamide sodium and prednisolone sodium phosphate have a boxed warning?
- No. None of the 2 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Sulfacetamide sodium and prednisolone sodium phosphate?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
- Has Sulfacetamide sodium and prednisolone sodium phosphate been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Sulfacetamide sodium and prednisolone sodium phosphate?
- 2 companies list prescription products of Sulfacetamide sodium and prednisolone sodium phosphate in the FDA NDC Directory, including NuCare Pharmaceuticals, Inc. and Bausch & Lomb Incoporated.
What Sulfacetamide sodium and prednisolone sodium phosphate is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Sulfacetamide Sodium and Prednisolone Sodium Phosphate Ophthalmic Solution is indicated for corticosteroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. …
— FDA label: Sulfacetamide Sodium and Prednisolone Sodium Phosphate, NuCare Pharmaceuticals,Inc., effective July 15, 2024. Read the full label on DailyMed →
Label quoted: the one for the most common form (solution/ drops, ophthalmic), Sulfacetamide Sodium and Prednisolone Sodium Phosphate, NuCare Pharmaceuticals,Inc.; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.
The FDA has 2 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 2 FDA labels for this medicine have a boxed warning.
Sulfacetamide sodium and prednisolone sodium phosphate side effects
Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.
Adverse reactions have occurred with corticosteroid/anti-infective combination drugs which can be attributed to the corticosteroid component, the anti-infective component, or the combination. Exact incidence figures are not available since no denominator of treated patients is available. Reactions occurring most often from the presence of the anti-infective ingredient are allergic sensitizations.
Read more of this section
Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias (see WARNINGS). Sulfacetamide sodium may cause local irritation. The reactions due to the corticosteroid component in decreasing order of frequency are: elevation of intraocular pressure (IOP) with possible development of glaucoma, and infrequent optic nerve damage; posterior subcapsular cataract formation; and delayed wound healing. Although systemic effects are extremely uncommon, there have been rare occurrences of systemic hypercorticoidism after use of topical corticosteroids. Corticosteroid-containing preparations can also cause acute anterior uveitis or perforation of the globe. Mydriasis, loss of accommodation and ptosis have occasionally been reported following local use of corticosteroids. Secondary Infection The development of secondary infection has occurred after use of combinations containing corticosteroids and antimicrobials. Fungal and viral infections of the cornea are particularly prone to develop coincidentally with long-term applications of corticosteroid. The possibility of fungal invasion must be considered in any persistent corneal ulceration where corticosteroid treatment has been used. Secondary bacterial ocular infection following suppression of host responses also occurs. To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb, a division of Valeant Pharmaceuticals North America LLC, at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
— FDA label: Sulfacetamide Sodium and Prednisolone Sodium Phosphate, NuCare Pharmaceuticals,Inc., effective July 15, 2024. Read the full label on DailyMed →
Sulfacetamide sodium and prednisolone sodium phosphate drug interactions
Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.
Sulfacetamide Sodium and Prednisolone Sodium Phosphate Ophthalmic Solution is incompatible with silver preparations. Local anesthetics related to p-aminobenzoic acid may antagonize the action of the sulfonamides.
— FDA label: Sulfacetamide Sodium and Prednisolone Sodium Phosphate, NuCare Pharmaceuticals,Inc., effective July 15, 2024. Read the full label on DailyMed →
Sulfacetamide sodium and prednisolone sodium phosphate dosage
Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.
Instill two drops of Sulfacetamide Sodium and Prednisolone Sodium Phosphate Ophthalmic Solution topically in the eye(s) every four hours. Not more than 20 mL should be prescribed initially. If signs and symptoms fail to improve after two days, patients should be re-evaluated (see PRECAUTIONS). Care should be taken not to discontinue therapy prematurely. In chronic conditions, withdrawal of treatment should be carried out by gradually decreasing the frequency of application.
Read more of this section
FOR OPHTHALMIC USE ONLY
— FDA label: Sulfacetamide Sodium and Prednisolone Sodium Phosphate, NuCare Pharmaceuticals,Inc., effective July 15, 2024. Read the full label on DailyMed →
Sulfacetamide sodium and prednisolone sodium phosphate in pregnancy
Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.
Teratogenic Effects Prednisolone has been shown to be teratogenic in rabbits, hamsters, and mice. In mice, prednisolone has been shown to be teratogenic when given in doses 1 to 10 times the human ocular dose. Dexamethasone, hydrocortisone and prednisolone were ocularly applied to both eyes of pregnant mice five times per day on days 10 through 13 of gestation. A significant increase in the incidence of cleft palate was observed in the fetuses of the treated mice.
Read more of this section
There are no adequate, well-controlled studies in pregnant women dosed with corticosteroids. Kernicterus may be precipitated in infants by sulfonamides given systemically during the third trimester of pregnancy. It is not known whether sulfacetamide sodium can cause fetal harm when administered to a pregnant woman or whether it can affect reproductive capacity. Sulfacetamide Sodium and Prednisolone Sodium Phosphate Ophthalmic Solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
— FDA label: Sulfacetamide Sodium and Prednisolone Sodium Phosphate, NuCare Pharmaceuticals,Inc., effective July 15, 2024. Read the full label on DailyMed →
Sulfacetamide sodium and prednisolone sodium phosphate and breastfeeding
Quoted from the nursing mothers / lactation part of the FDA-approved label.
It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Systemically administered sulfonamides are capable of producing kernicterus in infants of lactating women.
Read more of this section
Because of the potential for serious adverse reactions in nursing infants from sulfacetamide sodium and prednisolone sodium phosphate ophthalmic solution, a decision should be made whether to discontinue nursing or to discontinue the medication.
— FDA label: Sulfacetamide Sodium and Prednisolone Sodium Phosphate, NuCare Pharmaceuticals,Inc., effective July 15, 2024. Read the full label on DailyMed →
When Sulfacetamide sodium and prednisolone sodium phosphate should not be used
Quoted from the “Contraindications” section of the FDA-approved label.
Sulfacetamide Sodium and Prednisolone Sodium Phosphate Ophthalmic Solution is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.
Read more of this section
This product is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation, to other sulfonamides, or to other corticosteroids. (Hypersensitivity to the antimicrobial components occurs at a higher rate than for other components).
— FDA label: Sulfacetamide Sodium and Prednisolone Sodium Phosphate, NuCare Pharmaceuticals,Inc., effective July 15, 2024. Read the full label on DailyMed →
Forms and how it is given
| Dosage forms | Solution/ drops |
|---|---|
| Route | Ophthalmic |
| Prescription products | 2 in the FDA NDC Directory |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| prednisolone sodium phosphate 2.3 mg/mL · sulfacetamide sodium 100 mg/mL solution/ drops | Generic | $2.60 per mL |
NADAC list of November 11, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- NuCare Pharmaceuticals, Inc.1 product
- Bausch & Lomb Incoporated1 product
FDA approval history
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
Generic approvals (1)
- ANDA074449Bausch and Lomb · December 29, 1995
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 1012021 |
|---|---|
| SPL set ID of the quoted label | 835def0b-ed5a-61a0-e053-2a91aa0ae7ae |
| FDA labels (SPL) | 2 |
| FDA applications | 1 ANDA |
| Active ingredients (FDA) | PREDNISOLONE / SULFACETAMIDE |
Next steps
- Find a pharmacy near youAsk which price applies to you and whether your product is affected by a recall
- Latest FDA drug recallsAll medicines, newest first
- NuCare Pharmaceuticals, Inc.Maker or distributor
- Bausch & Lomb IncoporatedMaker or distributor
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Sulfacetamide Sodium and Prednisolone Sodium Phosphate, NuCare Pharmaceuticals,Inc., effective July 15, 2024; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →